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Abstract
Accumulating evidence suggests that multiple complex mechanisms may be involved, simultaneously or comple-
mentarily, in the emergence and development of multidrug resistance (MDR) in various cancers. Cell adhesion–
mediated MDR is one such mechanism. In the present study, we initially observed increased cell adhesion to
extracellular matrix proteins by the MDR human breast tumor cell line MCF-7/MX compared to its parental cells.
We then used a strategy that combined antibody-based screening technique and mass spectrometry–based pro-
teomics to identify membrane proteins that contribute to the enhanced adhesion of MCF-7/MX cells. Using MCF-7/
MX cells as immunogen, we isolated a mouse monoclonal antibody, 9C6, that preferentially reacts with MCF-7/MX
cells over the parental MCF-7 cells. The molecular target of 9C6 was identified as cytokeratin 8 (CK8), which was
found to be overexpressed on the cell surface of MCF-7/MX cells. We further observed that down-regulation of cell
surface levels of CK8 through siRNA transfection significantly inhibited MCF-7/MX cell adhesion to fibronectin and
vitronectin. In addition, anti-CK8 siRNA partially reversed the MDR phenotype of MCF-7/MX cells. Taken together,
our results suggest that alterations in the expression level and cellular localization of CK8 may play a significant role
in enhancing the cellular adhesion of MDR MCF-7/MX cells.
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Introduction
Multidrug resistance (MDR) is the phenomenon whereby tumor
cells acquire cross-resistance to a variety of structurally and function-
ally unrelated drugs. After cytotoxic chemotherapy, MDR occurs al-
most universally in various tumors and becomes a major obstacle to
successful cancer treatment. The complex multimodal mechanisms
involved in MDR have been extensively investigated and include
overexpression of a family of ATP-binding cassette (ABC) transporters,
such as P-glycoprotein (ABCB-1), multidrug resistance–associated
protein 1 (ABCC-1), and breast cancer resistance protein (BCRP;
ABCG-2), changes in topoisomerase II activity, and altered expression
of apoptosis-associated proteins and drug binding proteins [1–4].
Recently, accumulating evidence suggests that the extracellular micro-
environment may also influence the drug response and acquisition
of drug resistance in cancer cells [5,6]. Notably, cell adhesion has
been demonstrated to modulate drug response and prevent cell death,
implicating the interaction of cell-cell or cell–extracellular matrix as
a potentially important determinant in the emergence of drug resis-
tance [7,8].
Abbreviations: MDR, multidrug resistance; BCRP, breast cancer resistance protein;
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Indeed, increasing volumes of data stress that various molecular
mechanisms are concomitantly activated during cytotoxic drug expo-
sure and may complementarily and/or cooperatively contribute to
MDR phenotypes. Schneider et al. established a human breast cancer
cell line, MCF-7/MX, which was selected against mitoxantrone and
is cross-resistant to several cytotoxic agents, including mitoxantrone,
topotecan, and daunorubicin [9–11]. Expression of BCRP is signifi-
cantly up-regulated and is considered as the primary, but not the
only, contributing factor to drug resistance in MCF-7/MX cells
[10]. Initially, we found that the capacity of MCF-7/MX cells to
adhere to the extracellular matrix was increased compared to the pa-
rental cells. Therefore, we wondered whether the drug resistance of
MCF-7/MX cells is concomitantly associated with cell adhesion–
mediated MDR. To test this hypothesis, we first tried to identify
novel membrane molecules that participate in the enhanced adhesion
of MCF-7/MX cells. We used a mass spectrometry (MS)–based pro-
teomic approach to identify changes in membrane components be-
tween MCF-7/MX and parental cells.
However, owing to their inherently hydrophobic nature and low
abundance of membrane proteins, the success of direct differential
proteomics analysis to separate and identify membrane proteins is
limited [12,13]. Thus, we adopted an alternative strategy that com-
bines comparative antibody screening to identify the target antigen
with MS sequencing to identify differentially expressed proteins.
We immunized mice with MCF-7/MX cells and generated several
monoclonal antibodies that preferentially reacted with MCF-7/MX
compared to parental MCF-7 cells. One of the antibodies, 9C6,
bound to a unique epitope on cytokeratin 8 (CK8), which is found
to be overexpressed in the drug-resistant MCF-7/MX cells compared
to the drug-sensitive parental cells. Down-regulation of CK8 expres-
sion through siRNA transfection resulted in reduced cell adhesion
to the extracellular matrix and in partial reversal of the MDR pheno-
type in MCF-7/MX cells. Our results suggest that membrane CK8




The human breast cancer cell line MCF-7 and the mitoxantrone-
selected MDR cell line MCF-7/MX were kindly provided by Dr. E.
Schneider (Wadsworth Center, NY). All cell lines were grown as a
monolayer culture in Dulbecco’s modified Eagle’s medium (GIBCO,
Grand Island, NY) supplemented with 10% fetal calf serum (GIBCO)
at 37°C and 5% CO2. The drug-resistant cell line was cultured in mi-
toxantrone (Sigma, St. Louis, MO) at 800 ng/ml.
Comparative Screening of Hybridomas
BALB/c mice were immunized with MCF-7/MX cells (2 × 107)
through intraperitoneal injections, which were repeated three times
at 15-day intervals, until a positive test was obtained by ELISA. After
a final intrasplenic booster injection with MCF-7/MX cells (1 × 105),
splenocytes were harvested from mice with the highest antibody ti-
ters and fused to myeloma SP2/0 cells to generate hybridoma clones.
Comparative screening of hybridoma clone culture supernatants was
tested by ELISA. Briefly, parental MCF-7/WT and MDR MCF-7/
MX cells (5 × 104 cells per well) were seeded in 96-well plates and
cultured overnight. The cells were fixed in prechilled 0.1% glutaral-
dehyde (50% solution; Amresco, Solon, Ohio) for 15 minutes at 4°C
and blocked with 1% BSA in PBS overnight at 4°C. The hybridoma
supernatant (100 μl) was added to each well and incubated for
2 hours at room temperature. The plates were then incubated with
a horseradish peroxidase (HRP)–conjugated anti–mouse IgG anti-
body, followed by incubation with orthophenylenediamine (Sigma)
substrate. The plates were read at 490 nm using an ELISA reader
(Dynatech, Guernsey, UK). Sera from nonimmunized mice were
used as negative controls. Hybridoma clones producing antibodies
that showed preferential binding to MCF-7/MX compared to
MCF-7/WT cells were selected and subcloned three times by limit-
ing dilution. For large-scale antibody production, hybridoma clones
of interest were expanded and intraperitoneally injected into BALB/c
mice. Ascites were harvested, and antibodies were affinity-purified
using a Protein G–coupled Sepharose column according to the manu-
facturer’s protocol (Amersham Bioscience, Piscataway, NJ).
Immunoprecipitation and Western Blot
For immunoprecipitation, whole cell lysates were prepared in
modified RIPA buffer [50 mM Tris-HCl, 150 mM NaCl, 0.25%
SDS, 1% Triton X-100, 0.25% sodium deoxycholate, 1 mM EDTA,
1 mM EGTA, 1 mM dithiothreitol (DTT)] containing protease in-
hibitor cocktail (Sigma). Cell lysates containing 800 to 1000 μg of
total protein (at ∼1 mg/ml) were first incubated with 1 μg of isotype
control IgG antibody together with 20 μl of Protein A agarose sus-
pension (Sigma) with gentle shaking for 1 hour at 4°C. After centri-
fugation, the preabsorbed supernatants were incubated with 5 μg
of 9C6 at 4°C for 2 hours followed by 50 μl of Protein A–agarose
suspension overnight at 4°C with gentle shaking. The beads were
then pelleted through brief centrifugation and washed three times
with lysis buffer, and the proteins were then eluted by boiling the
sample in 2× SDS-PAGE loading buffer for 5 minutes. Sera from
nonimmunized mice were used as negative controls.
For immunoblot analysis, lysates containing 50 μg of total protein
were resolved by SDS-PAGE, transferred to nitrocellulose mem-
branes (Millipore, Billerica, MA), and blocked overnight at 4°C with
5% skim milk. The membrane was incubated with various primary
antibodies at room temperature, followed by HRP-conjugated sec-
ondary antibodies. All signals were visualized using SuperSignal West
Pico Chemiluminescent Substrate (Pierce, Rockford, IL) according
to the instructions of the manufacturer. The following antibodies
were used for immunoblot analysis: mouse monoclonal antibody
9C6 (0.5 μg/ml); ABCG2 (BXP-21, 1:1000; Alexis, San Diego, CA);
CK8 (C51, 1:1000); and GAPDH (6C5, 1:1000; Santa Cruz Bio-
technology, Santa Cruz, CA).
MALDI-TOF/TOF MS and MS/MS Analyses
The immunoprecipitated proteins were separated by 10% SDS-
PAGE gel and visualized by Coomassie Brilliant Blue staining. Bands
demonstrating a prominent differentiation between drug-sensitive
and drug-resistant cells were excised. In-gel digestion with trypsin
was performed using the following protocol. Briefly, the bands
were cut into tiny pieces, washed twice with ultrapure water, incu-
bated with 50 mM NH4HCO3 in 50% acetonitrile (enough to im-
merse the gel particles), and sonicated for 10 minutes. The solution
was removed, and the gel pieces were incubated in acetonitrile for
15 minutes at room temperature. The gel pieces were then vacuum
dried and reduced with 10 mM DTT in 25 mM NH4HCO3 for
1 hour at 56°C. The DTT solution was then replaced with the same
volume of 55 mM iodoacetamide in 25 mM NH4HCO3, followed
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by incubation for 45 minutes at room temperature in the dark. The
gel pieces were washed with 100 μl of 25 mM NH4HCO3 for
10 minutes while vortexing and dehydrated with 100 μl of 25 mM
NH4HCO3 in 50% acetonitrile. The liquid phase was removed,
and the gel pieces were again dried. The dried gel pieces were re-
swelled in 50 mM NH4HCO3 buffer containing trypsin (K/R) for
45 minutes at 4°C and then incubated at 4°C overnight. Trypsiniza-
tion was stopped with 5% trifluoroactic acid, and the supernatant
was assessed using a 4700 Proteomics Analyzer (Applied Biosystems,
Framingham, CA) operated in positive ion reflector mode with a m/z
range of 700 to 4000. Spectra were obtained by averaging 1000 ac-
quired spectra in MS mode or 3000 acquired spectra in MS/MS
mode. The MS/MS spectra of selected peptides from collision-
induced dissociation were obtained at an acceleration voltage of
1 keV and approximately 1 × 106 torr collision gas. The 4000 series
explorer software 3.0 (Applied Biosystems) was used for peak list gen-
erating with default parameters. Data were analyzed with GPS ex-
plorer 3.5 (Applied Biosystems) using Mascot Version 1.9.05 for peak
identification against the NCBInr human protein database (released
on May 28, 2007; 4880906 sequences, 1738906834 residues). The
search criteria permitted one missed cleavage, at least four matching
peptide masses, a mass tolerance of <50 ppm for precursor ions, a
mass tolerance of <0.2 Da for fragment ions, and a minimum signal-
to-noise ratio of 10.0. Variable modifications, including carbamido-
methyl modification and oxidation, were assigned to cysteine and
methionine residues, respectively. The peptide sequences were man-
ually reviewed for fidelity and consensus with known proteins. Sig-
nificant matches were identified based on an expected Mascot value
of <5% for protein identification, equivalent to statistically signifi-
cant search scores of >95%. Finally, the molecular weights of the pro-
teins were compared to the values estimated by gel electrophoresis.
Subcellular Fractions
Confluent cell monolayer were lysed in a hypotonic buffer (10 mM
HEPES pH 7.4, 25 mM KCl, 5 mM MgCl2, 5 mM EDTA) and
centrifuged at 200g for 10 minutes. The resulting pellet consisted
of nuclei and unhomogenized cells. The postnuclear lysates were
centrifuged at 20,000g for 20 minutes. The supernatant was designated
as the cytoplasmic fraction (C), whereas the resulting pellet was en-
riched in plasma membrane. The plasma membrane fraction was
solubilized in 1% Triton X-100, 0.5% sodium deoxycholate, and
0.1% SDS. After another centrifugation at 20,000g for 10 minutes,
the supernatant and pellet were collected as the detergent-soluble
membrane fraction (M-S) and detergent-insoluble membrane fraction
(M-P), respectively. Whole cell lysates (W) were prepared in modified
RIPA buffer or in 1× SDS-PAGE loading buffer containing 2% SDS,
5% 2-mercaptoethanol, and 25% glycerol in 0.05 M Tris-HCl buffer
(pH 6.8). Protease inhibitor cocktail was included at each stage
of preparation. Before SDS-PAGE, each fraction was adjusted to an
equal protein concentration using the BCA Protein Assay Kit (Pierce).
RNA Interference
CK8 siRNA and BCRP siRNA, each consisting of a pool of three
target-specific 20- to 25-nt siRNA designed to knockdown gene ex-
pression, were purchased from Santa Cruz Biotechnology and Invi-
trogen (Carlsbad, CA), respectively. The Stealth Select RNAi Set was
used to reduce off-target and nonspecific effects. A nonspecific siRNA
was also purchased from Invitrogen and used as the negative control.
MCF-7/MX cells (2.5 × 105 per well) were cultured in six-well
plates for 24 hours and transfected with 100 nM of the CK8 siRNA
or BCRP siRNA per well using LipofectAMINE 2000 (Invitrogen)
according to the manufacturer’s instructions. Control cells were in-
cubated with transfection reagent and the control nonspecific siRNA.
To confirm subsequent CK8 and BCRP knockdown, whole cell ly-
sates were prepared and subjected to Western blot analysis.
Immunofluorescence and Confocal Microscopy
Cells were grown on eight-well glass slides (Laboratory-Tek Brand
Products, Naperville, IL). To stain the plasma membrane, cells were
incubated with 2 μM CM-DiI (Invitrogen) for 5 minutes at 37°C
and then for an additional 15 minutes at 4°C. After two washes with
PBS, the cells were fixed with 4% (w/v) paraformaldehyde in PBS
at 37°C for 10 minutes and then blocked for 1 hour with PBS con-
taining 10% normal goat serum. The cells were then further incubated
with either clone 9C6 or C51, a commercially available anti-CK8
antibody (Santa Cruz Biotechnology), for 1 hour at 37°C, followed
by incubation with an FITC-conjugated goat anti–mouse secondary
antibody for 30 minutes at room temperature. Finally, DAPI (Sigma)
was applied at a final concentration of 1 μM in PBS for 10 minutes
to counterstain the nuclei. All images were obtained using a confocal
fluorescence microscope (Leica, Nussloch, Germany).
Cell Adhesion Assay
Ninety-six–well plates were first coated with either 10 or 20 μg/ml
of fibronectin (FN; Sigma-Aldrich, St. Louis, MO) or 5 or 10 μg/ml
of vitronectin (VN; BD Biosciences, San Diego, CA) in PBS at 4°C
overnight. Immediately before addition of the cells, the plates were
blocked with 0.5% BSA for 30 minutes at room temperature and
washed three times with PBS. All cells were harvested with 5 mM
EDTA in PBS and resuspended in DMEM containing 2% fetal bo-
vine serum at a concentration of 5 × 105 (MCF-7 and MCF-7/MX)
or 1 × 105 (HEK293) cells/ml. Then, 0.1 ml of cell suspension was
added to each well. The plates were incubated for 1 hour (MCF-7
and MCF-7/MX) or 30 minutes (HEK293) at 37°C and 5% CO2
and washed twice with PBS to remove unbound cells. The adherent
cells were fixed with 3% formaldehyde and stained with 30% ethanol
in PBS containing 0.5% crystal violet for 15 minutes. After two gen-
tle washes in PBS, 0.1 ml of DMSO was added to lyse the cells, and
the absorbance at 570 nm was read using a microtiter plate reader.
All data are presented as the mean ± SD of three determinations.
Statistical analysis was performed using a 2-tailed Student’s t test.
Cytotoxicity Assay
MCF-7/MX cells were transfected with siRNA as described above,
seeded in 96-well plates in triplicate at a density of 2000 cells per
well, and cultured overnight. The cells were incubated at 37°C in
5% CO2 for 48 hours with different drugs at the concentrations
indicated. Cell cytotoxicity was assayed using the optimized sulfo-
rhodamine B (SRB; Sigma) method as previously described [14].
Drug concentrations producing 50% cell growth inhibition (IC50)
were determined using curve-fitting analyses with Prism software
(GraphPad Software, San Diego, CA) using the following sigmoid
dose-response model equation: Y = Bottom + (Top − Bottom) / {1 +
10[(LogEC50 − X)]}. The IC50 values were calculated based on five in-
dependent experiments for each cell line. Statistical significance was
evaluated using the Mann-Whitney U test with SPSS software (Ver-
sion 16.0; SPSS, Chicago, IL).
Neoplasia Vol. 10, No. 11, 2008 Cell-surface Cytokeratin 8 and Cell Adhesion Liu et al. 1277
Results
Cell–Extracellular Matrix Adhesion Is Enhanced in
MCF-7/MX Cells
We first compared the adhesive activity of drug-resistant and drug-
sensitive cells. As shown in Figure 1, MCF-7/MX cells demonstrated
significantly greater cellular attachment to both FN and VN com-
pared to the parent cells. This suggests a discrepancy in cell adhesion
between drug-resistant and drug-sensitive cells.
Selective Screening of 9C6, a Monoclonal Antibody That Binds
Preferentially to MDR MCF-7/MX Cells
To identify cell surface molecules that are selectively up-regulated
in MDR MCF-7/MX cells compared to parent MCF-7 cells, we gen-
erated several monoclonal antibodies demonstrating preferential
binding to MDR cells over parent cells by immunizing mice with
MCF-7/MX cells. Clone 9C6 was selected for further studies based
on its strong and selective reactivity with MCF-7/MX cells (Figure 2A).
Western blot analysis using whole cell lysate demonstrated that
9C6 binds to a single protein band of approximately 53 kDa in both
MCF-7 and MCF-7/MX cells (Figure 2B). As expected, the expression
level of the protein recognized by 9C6 was much higher in MDR cells.
Identification of the Differential Expression of CK8 by
MALDI-TOF/TOF MS
Immunoprecipitation was performed with 9C6 using whole cell
lysates from both MCF-7 and MCF-7/MX cells, and immunocom-
plexes were resolved by SDS-PAGE analysis. Commassie blue stain-
ing of the gel revealed two unique protein bands of approximately
53 and 48 kDa, respectively (Figure 3A). Only upper band #1, how-
ever, was recognized by 9C6 when the gel was subjected to Western
blot analysis (Figure 3B). The two protein bands were excised and
analyzed by MALDI-TOF/TOF MS, followed by database interroga-
tion. The MS/MS data obtained for five peptides from the 53-kDa
band matched CK8 based on a total of 301 ion scores (accession
number gi|49256423 in the NCBI database; Table 1). In contrast,
the MS/MS data obtained for four peptides from the 48-kDa band
matched cytokeratin 18 based on 208 ion scores (accession number
gi|61357801 in the NCBI database; data not shown). It is known
that CK8 and CK18 form a heterotypic network in a wide variety of
epithelial cells. Thus, CK18 was identified here by coimmunoprecipi-
tation with 9C6, further confirming CK8 to be the specific target rec-
ognized by 9C6.
Characterization of Membrane CK8 Expression in MDR
MCF-7/MX Cells
To confirm the proteomic results described above and provide fur-
ther evidence that the protein recognized by 9C6 was indeed CK8,
Western blot analysis was repeated using a commercial monoclonal
antibody, C51, which has been shown to react specifically with CK8.
As shown in Figure 4A, both the C51 and 9C6 antibodies yielded
identical patterns of immunoreactivity with the 53-kDa protein
when blotted against whole cell lysate. As a control, neither antibody
detected any protein bands when applied to blots of whole cell ly-
sate from NIH3T3 cells, which are known to not express CK8
(Figure 4A). In a parallel experiment, whole cell lysate was first im-
munoprecipitated with 9C6 or a control IgG antibody, followed by
blot analysis with C51. As shown in Figure 4B, the 53-kDa protein
was only observed in the 9C6-precipitated sample, further confirm-
ing the binding specificity of 9C6 for CK8 protein.
The expression pattern of CK8 in different subcellular fractions
was then compared between drug-sensitive and drug-resistant cells
(Figure 4C ). As expected, BCRP expression was significantly elevated
in MDR MCF-7/MX cells and was located exclusively in the plasma
membrane fractions (M-S and M-P). Consistent with an earlier ob-
servation, CK8 expression, as detected by both 9C6 and C51, was
significantly increased in the MDR cells, especially in the detergent-
insoluble portion (M-P) of the plasma membrane fraction. Similar
to the Western blot analysis, immunofluorescence confocal micros-
copy confirmed the distinct membrane staining patterns of CK8 be-
tween MCF-7/MX and MCF-7 cells. As shown in Figure 4D, 9C6
exhibited much stronger plasma membrane staining in MCF-7/MX
cells compared to that in MCF-7 cells, further confirming the sur-
face overexpression of CK8 in MDR cells. Upon cell membrane
permeabilization, 9C6 yielded clear cytoplasmic staining in both
MCF-7/MX and MCF-7 cells (data not shown). In contrast, C51,
while demonstrating clear cytoplasmic staining in both permeabilized
MCF-7/MX and MCF-7 cells, failed to bind to the plasma mem-
brane of MCF-7/MX cells (Figure 4E ). It seems apparent that the
binding epitope(s) on CK8 recognized by 9C6 and C51 are different;
unlike 9C6, C51 may bind to an epitope that is not exposed on the
cell surface.
Increased Cell Surface CK8 Expression Caused Enhanced Cell
Adhesion in MDR MCF-7/MX Cells
To determine whether increased CK8 expression in MCF-7/MX
cells is involved in their enhanced adhesion, a siRNA-silencing ap-
proach was used to down-regulate the expression of CK8. MCF-7/
MX cells were transfected with anti-CK8 siRNA. The optimal con-
centration of both anti-CK8 siRNA for cell transfection was deter-
mined based on a series of titration experiments to be 100 nM (data
not shown). As shown in Figure 5A, transfection of anti-CK8 siRNA
resulted in significant down-regulation of the expression of the respec-
tive proteins 48 to 96 hours after transfection. As expected, the control
Figure 1. Comparison of cell–extracellularmatrix adhesion inMCF-7/
MX and drug-sensitive cells. Drug-sensitiveMCF-7 andMDRMCF-7/
MX cells (5 × 104 cells per well plated in 96-well plates in DMEM
containing 2% FBS) were incubated in FN- or VN-coated plates for
1 hour at 37°C and 5% CO2. Cell attachment was quantitated using
the crystal violent adhesion assay as described in the Materials
and Methods section. *P < .01, MCF-7/MX versusMCF-7.
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siRNA did not show any effects on CK8 expression 48 and 96 hours
after transfection. Most importantly, in addition to the reduced expres-
sion in whole cell lysate, immunofluorescence staining showed that
the surface expression of CK8 inMCF-7/MX cells was also significantly
down-regulated after transfection with anti-CK8 siRNA (Figure 5C). In
contrast, the siRNA-mediated down-regulation of BCRP had no effect
on the cell surface expression of CK8 in MCF-7/MX cells (Figure 5, B
and C ). Taken together, these results confirm both the efficacy and
specificity of our siRNA silencing approach.
We next assessed the possible role of membrane CK8 in cell ad-
hesion by specifically down-regulating membrane CK8 by RNA in-
terference. Down-regulation of CK8 expression effectively reduced
cell-FN and cell-VN adhesion in MCF-7/MX cells; however, a less
obvious change in drug-sensitive cells was also observed (Figure 6, A
Figure 2. Identification of 9C6, a monoclonal antibody that preferentially binds to MDR MCF-7/MX cells. (A) Binding of the 9C6 hybrid-
oma culture supernatant to parental drug-sensitive MCF-7 cells and MDR MCF-7/MX cells by ELISA. Nonimmunized mouse serum
was used as a negative control. Data are presented as the mean ± SD of three independent experiments. *P < .05 versus MCF-7.
(B) Western blot analysis of whole cell lysates using 9C6. Molecular mass standards (in kDa) are shown on the left.
Figure 3. Separation of proteins recognized specifically by 9C6. The 9C6 and control IgG antibodies were used for immunoprecipitation
with whole lysates from MCF-7 and MDR MCF-7/MX cells. The precipitated proteins were separated by SDS-PAGE and visualized by
Commassie blue staining (A) or by Western blot analysis using 9C6 (B). The IgG heavy chains (∼56 kDa) and light chains (∼25 kDa) were
also identified in the gel and blot. Arrows indicate the positions of the protein bands that were subjected to mass spectrometry analysis.
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and C ). Because the expression levels of CK8 in both the cell mem-
brane and cytoplasm were reduced by suppression of cytoplasmic
CK8, it was necessary to further investigate whether the increased
cell adhesion was only affected by membrane CK8 rather than by
cytoplasmic CK8. Thus, the same assessment was carried out in
adenovirus-transformed human embryonic kidney cells (HEK293),
which demonstrate strong expression of CK8 only in the cytoplasm,
using 9C6 (data not shown). Remarkably, CK8 siRNA did not
change the adhesive properties HEK293 cells, although the expres-
sion of intracellular CK8 was significantly knocked down. These re-
sults suggest that membrane CK8, but not cytoplasmic CK8, played
an important role in enhancing the attachment of drug-resistant
MCF-7/MX cells to FN and VN. In addition, siRNA-mediated
down-regulation of BCRP expression had no effect on the adhesion
of MCF-7/MX cells (Figure 6, B and D).
CK8 Partially Contributed to Drug Resistance in MDR
in MCF-7/MX Cell
The effect of siRNA-mediated down-regulation of CK8 and
BCRP expression on the MDR phenotype of MCF-7/MX cells
was examined. Drug sensitivity of the various transfected tumor cells
to three cytotoxic agents, mitoxantrone, topotecan, and daunorubicin,
was investigated. As shown in Table 2, MDR MCF-7/MX cells
showed 1112-, 322-, and 3.7-fold increased resistance to mitoxan-
trone, topotecan, and daunorubicin, respectively, compared to its
parental MCF-7 cells. Down-regulation of CK8 expression by siRNA
significantly increased drug sensitivity of MCF-7/MX cells by ap-
proximately 40.2%, 33.0%, and 62.2%, to mitoxantrone, topotecan,
and daunorubicin, respectively (P < .01 in all three cases). Meanwhile,
down-regulation of BCRP expression in MCF-7/MX cells by siRNA
transfection resulted in a more drastic drug sensitization: cell resis-
tance to mitoxantrone, topotecan, and daunorubicin was reduced by
76.8%, 63.1%, and 100%, respectively (all P < .01; Table 2).
Discussion
In our initial study, we have found a salient discrepancy in cell ad-
hesion between MDR MCF-7/MX cells and drug-sensitive MCF-7/
WT cells, but the mechanism remains unclear. To examine the possi-
ble mechanisms that contribute to the enhanced adhesion of MDR
cells, we set out to investigate potential membrane proteins that dem-
onstrate differential expression in MDR breast cancer cells. By im-
munizing mice with an MDR MCF-7/MX cell line, we obtained an
antibody that specifically reacts with CK8. The antibody preferen-
tially binds to the surface of MCF-7/MX cells compared to their
Table 1. Identification of CK8 by Mass Spectrometry.
Calculated Mass Observed Mass ± da Start Sequence End Sequence Sequence
911.4217 911.3864 −0.0353 24 32 SYTSGPGSR
1079.5116 1079.4653 −0.0463 265 273 AQYEDIANR
1208.5939 1208.5443 −0.0497 303 312 TKTEISEMNR
1277.7101 1277.7314 0.0214 382 392 LALDIEIATYR
1341.7484 1341.6884 −0.0601 317 328 LQAEIEGLKGQR
1344.6754 1344.6198 −0.0556 329 341 ASLEAAIADAEQR
1352.6766 1352.6122 −0.0644 187 197 TEMENEFVLIK
1405.8049 1405.7451 −0.0598 382 393 LALDIEIATYRK
1412.6838 1412.6245 −0.0593 274 285 SRAEAESMYQIK
1419.7478 1419.7799 0.0321 214 225 LEGLTDEINFLR
1428.6787 1428.6119 −0.0668 274 285 SRAEAESMYQIK
1480.7716 1480.7017 −0.0699 187 198 TEMENEFVLIKK
1508.7777 1508.7146 −0.0631 186 197 RTEMENEFVLIK
1797.8323 1797.7588 −0.0735 199 213 DVDEAYMNKVELESR
1847.8051 1847.8541 0.049 134 148 SNMDNMFESYINNLR
1956.0396 1955.9664 0.0733 329 347 ASLEAAIADAEQRGELAIK
2003.9062 2003.8374 0.0688 134 149 SNMDNMFESYINNLRR
2034.0576 2033.9888 −0.0688 159 176 LKKLEAELGNMQGLVEDFK
2109.0129 2108.9451 −0.0678 234 252 ERLQSQISDTSVVLSMDNSR
#1 band in SDS-PAGE was cut, digested by trypsin, and analyzed by mass spectrometry. Measured masses from MALDI-TOF, theoretical masses from NCBInr human protein database, their difference
(±da), and the corresponding sequence in CK8 were shown for each matched peptide. Sequences underlined were also obtained by MS/MS. After MALDI-TOF MS and database searching, 19 tryptic
peptides matched with theoretical masses, leading to a sequence coverage of 38.3%.
Figure 4. Increased expression of CK8, both intracellularly and on the cell surface, of MDR MCF-7/MX cells. (A) Western blot analysis of
whole cell lysates (W) with 9C6 or commercial the anti-CK8 antibody, C51. A protein band of the same molecular weight was identified
by both antibodies. NIH3T3 and HEK293 cell lines were used as negative and positive control, respectively. (B) Western blot analysis
of immunocomplexes precipitated by 9C6 or a control IgG using C51 as the blotting agent. Note that 9C6 yielded a single protein band
at ∼53 kDa, whereas no specific protein band was identified in the control IgG sample. IgG heavy chains (∼55 kDa) and light chains
(∼25 kDa) were also identified in the blots. WT indicates parent MCF-7 cells; MX, MCF-7/MX cells. (C) Western blot analysis of the
subcellular protein fractions from MCF-7 and MCF-7/MX cells. C indicates cytoplasmic fraction; M-S, detergent-soluble portion of
the plasma membrane fraction; M-P, detergent-insoluble pellet from the plasma membrane fraction. BCRP and GAPDH were used
to assess the purity of the membrane and cytoplasmic fractions, respectively. (D–E) Immunofluorescence staining of cell membrane
CK8. Cell surface CK8 expression was detected (in green) using 9C6 (D) or C51 (E) in fixed, nonpermeabilized MCF-7 and MCF-7/MX
cells. The plasma membrane was further stained with CM-DiI (red), whereas the nuclei were stained with DAPI (blue). Note that surface
CK8 staining in MCF-7/MX cells using 9C6 was significantly stronger than that in MCF-7 cells, whereas no obvious membrane CK8
staining was observed when using C51. The merged images clearly demonstrate costaining (yellow) in the MCF-7/MX cell membrane
with both 9C6 and CM-DiI.
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parental MCF-7 cells, providing direct evidence of the cell surface
overexpression of CK8 in MDR MCF-7/MX cells. It has been a sub-
ject of debate whether cell surface expression of CK8 under various
experimental conditions represents a true phenomenon associated
with cell transformation or just an artifact of study methods. In our
preliminary experiment, we failed to identify cell surface CK8 through
N-terminal biotinylation of intact cells (data not shown). This is con-
sistent with the observations of Riopel et al. [15]. Conversely, a num-
ber of reports have clearly demonstrated that CK8 is expressed on
the surface of a number of cancer cell lines, especially MCF-7 cells
[16,17]. For example, by combining cell surface iodination and two-
dimensional electrophoresis methods, Godfroid et al. [16] demon-
strated that CK8, CK18, and CK19 are expressed on the surface of
several established human breast cancer cell lines, including MCF-7
cells. Ultrastructural immunocytochemistry further confirmed that
cytokeratins were localized to the blebs formed by the cell membrane.
Similarly, CK8 was shown to localize to the plasma membrane of
cancer cells but was absent on the cell membrane of other healthy hu-
man tissues, excluding hepatocytes, based on confocal laser scanning
microscopy [17].
Several potential mechanisms have been proposed for the aberrant
expression of CK8 on the tumor cell surface, including lipid binding
followed by translocation to the outer membrane [18], penetration
and projection through the plasma membrane as part of a protein
complex [19,20], and noncovalent association, or secondary binding,
to the cell membrane after proteolytic release from cells into the
extracellular space [21–23]. Overproduction of cytokeratins by trans-
formed cells may also lead to increased cell surface expression because
of insufficient incorporation into intermediate filaments [24]. It is
also noteworthy that a truncated form of CK8 was identified in colo-
rectal cancer cells (but not in normal colon cells), suggesting that ma-
lignant cells may possess CK8 degradation pathways that differ from
those of normal cells [25].
What are the exact physiological and pathological roles of cell
surface–expressed CK8 remains a question to be clearly elucidated. Sev-
eral reports have demonstrated that CK8 is able to bind plasminogen
and promote its activation through tissue-type plasminogen activator
on the cancer cell surface, suggesting that cell surface CK8may function
as a major plasminogen receptor and contribute to cancer invasion and
metastasis [19,26,27]. Here, we report the positive correlation between
membrane CK8 and cell adhesion in MDR cancer cells, adding further
comprehensive information to the function of membrane CK8. We
demonstrated that cell surface overexpression of CK8 led to increased
attachment of MCF-7/MX cells to FN and VN, and this effect could
Figure 5. Modulation of CK8 and BCRP expression by specific siRNA. (A–B) Analysis of siRNA-mediated knockdown of CK8 or BCRP
protein expression in MCF-7/MX cells by Western blot. RNAi interference was performed using (A) anti-CK8 siRNA and (B) anti-BCRP
siRNA at a concentration of 100 nM. CK8 or BCRP expression at the indicated time points (48, 72, and 96 hours) after siRNA transfection
was assessed by Western blot analysis using C51 and BXP-21. (C) Immunofluorescence staining of surface CK8 on MCF-7/MX cells after
siRNA transfection. MCF-7/MX cells treated with anti-CK8 siRNA or anti-BCRP siRNA were incubated with 9C6 for 1 hour at 37°C, fol-
lowed by staining with an FITC-conjugated goat anti–mouse antibody for 30 minutes at room temperature (green). The plasma mem-
brane was further stained with CM-DiI (red), and the nuclei were stained with DAPI (blue). Note that anti-BCRP siRNA transfection did
not result in a decrease in the surface CK8 expression of MCF-7/MX cells.
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be completely reversed by anti-CK8 siRNA transfection. To date,
studies examining BCRP function have focused on its efflux of cytotoxic
agents, and no such correlation of BCRP expression with cell adhesion
has been reported. Consistent with this, we did not detect any effects
of BCRP on cell–extracellular matrix adhesion in MCF-7/MX cells,
although BCRP is also highly expressed on the cell surface of MCF-7/
MX cells.
There is a great deal of evidence suggesting that cell-cell and cell–
extracellular matrix adhesion could mediate drug resistance through
different mechanisms in cancer cells [28–30]. For example, attach-
ment of tumor cells to FN through certain integrins has been shown
to protect the cells from drug-induced apoptosis and confer an MDR
phenotype [29,31]. Furthermore, overexpression of PECAM-1 in
lymphoid cancers has been shown to confer resistance to apoptosis
induced by DNA-damaging chemotherapeutic agents, and decreased
PECAM-1 expression could render cancer cells more susceptible to
chemotherapy [30]. Similarly, an anti–E-cadherin antibody has been
found to increase the chemosensitivity of MCF-7 cells, which express
a high level of E-cadherin [32]. Therefore, we further examined the
role of overexpressed membrane CK8 in drug resistance to investi-
gate whether adhesion-mediated drug resistance is also exhibited by
MDR MCF-7/MX cells. It is intriguing that reduced cell surface
CK8 expression by CK8 siRNA transfection partially restored the
sensitivity of MCF-7/MX cells to all three chemotherapeutic agents
tested (Table 2), clearly supporting the notion that membrane CK8
may be involved in cellular protection against chemotherapeutic
agents in MDR MCF-7/MX cells; although the BCRP-mediated
Table 2. Effects of siRNA Transfection on Chemosensitivity of MCF-7/MX Cells.
Cells IC50 (RR)*
,†
Mitoxantrone (nM) Topotecan (nM) Daunorubicin (nM)
MCF-7 22.13 ± 1.60 (1) 54.99 ± 5.82 (1) 116.53 ± 10.98 (1)
MCF-7/MX 24,610 ± 1085 (1112) 17,759 ± 1265 (322) 427.13 ± 15.41 (3.7)
siRNA-Control 22,491 ± 982 (1016) 16,867 ± 1978 (306) 433.73 ± 4.48 (3.7)
siRNA-CK8 13,450 ± 1087 (608)‡ 11,311 ± 658 (205)‡ 163.80 ± 32.39 (1.4)‡
siRNA-BCRP 5232 ± 348 (236)‡ 5201 ± 733 (95)‡ 122.17 ± 17.10 (1.0)‡
*IC50 values (mean ± SD) were calculated from five independent experiments performed in
triplicates.
†RR indicates relative resistance (x-fold compared to that of MCF-7 cells).
‡P < .01 compared to the control siRNA-treated cells.
Figure 6. Membrane CK8 mediates enhanced cell adhesion of MDR MCF-7/MX cells to FN and VN. (A and C) MCF-7, MCF-7/MX, and
HEK293 cells were transfected with anti-CK8 siRNA or a control siRNA. After 48 hours, the cells were harvested and analyzed using the
cell adhesion assay by coating plates with FN (20 μg/ml) or VN (10 μg/ml). Note that anti-CK8 siRNA significantly inhibited the cell ad-
hesion of MCF-7/MX cells to FN and VN to a comparable level exhibited by parent MCF-7 cells. In contrast, anti-CK8 siRNA showed only
a marginal effect on MCF-7 cells and did not affect the attachment of HEK293 cells. (B and D) MCF-7 and MCF-7/MX cells were trans-
fected with anti-BCRP siRNA. Note that anti-BCRP siRNA have no effects on the cell–extracellular matrix adhesion in both cell lines. Data
are shown as the mean ± SD of triplicate determinations.
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MDR phenotype is still a major contributor. It is likely that CK8
enhances adhesion between cells and cell–extracellular matrix pro-
teins through its increased surface expression and, as a result, mediates
drug resistance. However, it is also plausible that the up-regulation
of CK8 may be the result of prolonged exposure of MCF-7 cells to
mitoxantrone, a secondary effect of cellular response to the drug, rather
than the primary cause of resistance to the compound. Further,
although a number of studies have unequivocally demonstrated in-
creased CK8 expression in MDR tumor cells, there was at least one re-
port showing that CK8 was underexpressed in both adriamycin- and
paclitaxel-resistant breast tumor cells [33]. More in-depth mechanistic
studies are clearly warranted to further elucidate the relevance and the
roles of CK8 expression in the development of MDR in tumor cells.
In summary, we demonstrated that CK8 expression is up-regulated
on the cell surface of the MDR human breast cancer cell line, MCF-7/
MX. Down-regulation of CK8 in MCF-7/MX cells using the siRNA
approach significantly reduced tumor cell adhesion to extracellular
matrix proteins and partially reversed the MDR phenotype in tumor
cells. Taken together, our results suggest that tumor surface–expressed
CK8, through enhancing cell–cell matrix adhesion, may represent a
complementary mechanism of MDR in MCF-7/MX cells. Further
understanding of the molecular mechanisms involved in the emergence
and maintenance of MDR is essential for the development of novel and
more effective agents for efficient diagnosis and therapy for cancer.
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